This observational study is looking at how a special imaging agent called F 18 T807 helps us understand Alzheimer's disease. Participants will receive a single injection of F 18 T807, which is a radioactive tracer, and then have a PET scan. This helps researchers see tau fibrils in the brain, which are abnormal protein clumps linked to Alzheimer's. The study aims to see if the amount of F 18 T807 uptake in the brain correlates with a person's thinking abilities and other brain scans. This could help detect cognitive decline very early. The study is open to adults aged 18 and older who are cognitively normal or have mild dementia. The goal is to see if this imaging technique can be an early indicator of cognitive decline. The current status of the study is unclear.

Study design

This is a single-center, open-label, baseline-controlled observational imaging study with a planned enrollment of 900 participants.

What's involved

You would receive a single intravenous injection of F 18 T807 and undergo imaging tests like MRI or CT, and PET scans. A lumbar puncture (LP) may also be part of the testing.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, F 18 T807 Standard Uptake Value Ratios (SUVR), will be measured at 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.